Zhongguo Dang Dai Er Ke Za Zhi. 2022 Mar 15;24(3):225-231. doi: 10.7499/j.issn.1008-8830.2112033.
Kawasaki disease (KD) is one of the common acquired heart diseases in under-5-year-old children and is an acute self-limiting vasculitis. After nearly 60 years of research, intravenous immunoglobulin combined with oral aspirin has become the first-line treatment for preventing coronary artery aneurysm in the acute stage of KD. However, glucocorticoid (GC), infliximab, and other immunosuppressants are options for the treatment of KD patients with a high risk of coronary artery aneurysm, no response to intravenous immunoglobulin and a confirmed diagnosis of coronary artery aneurysm. At present, there are still controversies over the use of GC in the treatment of KD. With reference to the latest research findings of KD treatment in China and overseas, this consensus invited domestic pediatric experts to fully discuss and put forward recommendations on the indications, dosage, and usage of GC in the first-line and second-line treatment of KD.
川崎病（KD）是5岁以下儿童常见的后天性心脏病之一，是一种急性自限性血管炎。经过近60年的研究，静脉注射免疫球蛋白联合口服阿司匹林已成为KD急性期预防冠状动脉瘤的一线治疗方法。然而，糖皮质激素（GC）、英夫利昔单抗和其他免疫抑制剂是治疗冠状动脉瘤高危、对静脉注射免疫球蛋白无反应且确诊为冠状动脉瘤的KD患者的选择。目前，GC在KD治疗中的应用仍存在争议。参考国内外KD治疗的最新研究结果，本共识邀请国内儿科专家就GC在KD一线和二线治疗中的适应证、剂量和用法进行充分讨论并提出建议。
